76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Laboratorios Farmaceuticos Rovi SA
Open
SectorHealthcare
52 -2.26
Overview
Share price change
24h
Min
51.7
Max
53
Income | -57M 32M |
|---|---|
Sales | 199M 434M |
P/E Sector Avg | 19.029 54.533 |
EPS | 0.354 |
Dividend yield | 1.8 |
Profit margin | 7.411 |
Employees | 2,197 |
EBITDA | 40M 138M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +47.39% upside |
Dividend yield Sector Avg | 1.80% 2.41% |
|---|---|
Next Earnings | 30 Jul 2025 |
Market Cap | -707M 2.7B |
|---|---|
Previous open | 54.26 |
Previous close | 52 |
News Sentiment
By Acuity
50%
50%
187 / 382 Healthcare
Technical Score
By Trading Central
Confidence
Weak Bullish Evidence
Laboratorios Farmaceuticos Rovi SA Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Laboratorios Farmaceuticos Rovi SA Forecast
Price Target
By TipRanks
47.39% upside
12 Months Forecast
Average 77.75 EUR 47.39%
High 90 EUR
Low 65.5 EUR
Based on 2 Wall Street analysts offering 12 month price targets forLaboratorios Farmaceuticos Rovi SA - Dist in the last 3 months.
Sentiment
By Acuity
187 / 382 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Laboratorios Farmaceuticos Rovi SA
Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
